Cas no 526-08-9 (Sulfaphenazole)
Sulfaphenazole Chemical and Physical Properties
Names and Identifiers
-
- Benzenesulfonamide,4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-
- Sulfaphenazole
- 4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide
- 4-amino-N-(2-phenylpyrazol-3-yl)benzenesulfonamide
- Depotsulfonamide
- Eftolon
- Firmazolo
- Inamil
- Isarol
- Isarol V
- Merian
- Microtan pirazolo
- N1-(1-Phenylpyrazol-5-yl)sulfanilamide
- Sulphaphenazole
- Sulfabid
- Sulfaphenazon
- Sulfaphenazol
- Raziosulfa
- Sulfafenazol
- Plisulfan
- Depocid
- Sulphenazole
- Sulfaphenylpyrazole
- Sulfaphenylpipazol
- Sulfafenazolo
- Sulfaphenazolum
- Paidazolo
- Orisul
- 1-Phenyl-5-sulfanilamidopyrazole
- 5-Sulfanilamido-1-phenylpyrazole
- Sulfaphenylpyrazol
- Phenylsulfapyrazole
- Sulfafenazolo [Italian]
- N'-(1-Phenylpyrazol-5-yl
- N(1)-(1-Phenylpyrazol-5-yl)sulfanilamide
- NCGC00015925-02
- EN300-7419010
- SR-01000075649-8
- Sulfabid (TN)
- SULFAPHENAZOLE [MI]
- NCGC00015925-05
- N(sup 1)-(1-Phenylpyrazol-5-yl)sulfanilamide
- 0J8L4V3F81
- Sulfonylpyrazol
- 1420043-53-3
- Sulfanilamide, N1-(1-phenylpyrazol-5-yl)-
- Lopac-S-0758
- 4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide
- SULFAPHENAZOLE [MART.]
- NCGC00015925-03
- BRD-K10671814-001-09-8
- Sulfaphenazole, >=98%
- Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-
- Solfafenazolo [DCIT]
- Tox21_110262
- BRN 0308518
- HMS1568E03
- KBio2_007022
- HMS500P05
- Prestwick2_000021
- CAS-526-08-9
- 4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benze-ne-13C6-sulfonamide
- Prestwick0_000021
- AB00052218
- CHEMBL1109
- Sulfaphenazole, >=98% (HPLC)
- CS-4843
- Spectrum3_001741
- NSC757859
- NCGC00015925-17
- Sulfaphenazol (INN-French)
- MLS000859612
- KBio2_004454
- Spectrum_001406
- KBio2_001886
- NCGC00094368-04
- NINDS_000303
- NCGC00015925-08
- Orisulf
- KBioGR_000826
- NCGC00015925-06
- Spectrum4_000443
- Spectrum2_001943
- Sulfanilamide, N(sup 1)-(1-phenylpyrazol-5-yl)-
- SPBio_002002
- BIM-0051065.0001
- EINECS 208-384-3
- Prestwick_454
- NS00006369
- HMS3712E03
- Sulfaphenazolum (INN-Latin)
- GTPL11352
- Sulfafenazol (INN-Spanish)
- SPECTRUM1501143
- DB06729
- HMS1921J13
- UNII-0J8L4V3F81
- BDBM50090677
- KBio3_002662
- SCHEMBL122040
- MLS001056713
- SMR000326684
- NCGC00094368-05
- SDCCGSBI-0051065.P004
- 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)benzene-1-sulfonamide
- S 0758
- HMS2235J21
- NCGC00261780-01
- Sulfaphenazol [INN-French]
- Tox21_501095
- LP01095
- SR-01000075649-2
- 526-08-9
- AB00052218_10
- Pyrazole, 1-phenyl-5-sulfanilamido-
- MFCD00057226
- NSC 757859
- KBioSS_001886
- NCGC00094368-02
- STR05485
- NCGC00015925-01
- Q6577293
- NCGC00015925-10
- N'-(1-Phenylpyrazol-5-yl)sulfanilamide
- 5-25-09-00415 (Beilstein Handbook Reference)
- CCG-39431
- NCGC00015925-12
- Prestwick1_000021
- BPBio1_000091
- SR-01000075649-9
- J01ED08
- BSPBio_003442
- SULFAPHENAZOLE [INN]
- BRD-K10671814-001-05-6
- DTXCID0024131
- BCP27626
- EU-0101095
- NCGC00094368-01
- Tox21_110262_1
- NSC-757859
- BRN-0308518; BRN0308518; BRN 0308518;Sulfabid;Sulfaphenylpyrazol;Sulphaphenazole
- s3673
- DTXSID2044131
- NCGC00015925-13
- NCGC00094368-03
- NCGC00015925-07
- Sulfaphenazole 100 microg/mL in Acetonitrile
- 1ST4057
- HMS3373E16
- HMS2095E03
- SULFAPHENAZOLE (MART.)
- NCGC00015925-09
- SPBio_002005
- D70410
- FT-0761575
- 3-(p-Aminobenzenesulfonamido)-2-phenylpyrazole
- DivK1c_000303
- SULFAPHENAZOLE [WHO-DD]
- SBI-0051065.P003
- SULFAPHENAZOLE [JAN]
- Sulfaphenazole (JAN/INN)
- Spectrum5_001185
- Lopac0_001095
- Sulfaphenazolum [INN-Latin]
- Sulfaphenazole [INN:BAN:JAN]
- BSPBio_000081
- Pharmakon1600-01501143
- 4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide
- Sulfafenazol [INN-Spanish]
- CHEBI:77780
- Sulfaphenazole-d4
- Prestwick3_000021
- SULFAPHENAZOLE [ORANGE BOOK]
- SR-01000075649-7
- D01954
- SR-01000075649
- AKOS003348743
- Solfafenazolo
- HY-B1218
- NCGC00015925-04
- IDI1_000303
- HMS3263K12
- KBio1_000303
- BRD-K10671814-001-14-8
- STK663863
- Sulfaphenazole?
- DA-67841
- ALBB-025160
-
- MDL： MFCD00057226
- Inchi： 1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2
- InChI Key： QWCJHSGMANYXCW-UHFFFAOYSA-N
- SMILES： S(C1C=CC(=CC=1)N)(NC1=CC=NN1C1C=CC=CC=1)(=O)=O
Computed Properties
- Exact Mass: 314.08400
- Monoisotopic Mass: 314.084
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 22
- Rotatable Bond Count: 4
- Complexity: 451
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 1.5
- Topological Polar Surface Area: 98.4
- Surface Charge: 0
- Tautomer Count: 3
Experimental Properties
- Density: 1.39
- Melting Point: 179-183?°C
- Boiling Point: 541.9°C at 760 mmHg
- Flash Point: 281.5°C
- Refractive Index: 1.6440 (estimate)
- PSA: 98.39000
- LogP: 3.99030
Sulfaphenazole Security Information
- Signal Word：Warning
- Hazard Statement： H302
- Warning Statement： P280-P305+P351+P338
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：2
- Safety Instruction： 24/25
- RTECS：DA9520000
- Toxicity：LD50 orally in mice: 5800 mg/kg (Seki)
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Sulfaphenazole Customs Data
- HS CODE：2935009090
- Customs Data：
China Customs Code:
2935009090Overview:
2935009090 Other sulphonates(Acyl)amine. VAT:17.0% Tax refund rate:9.0% Regulatory conditions:nothing MFN tariff:6.5% general tariff:35.0%
Declaration elements:
Product Name, component content, use to
Summary:
2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%
Sulfaphenazole Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| DC Chemicals | DC26155-100 mg |
Sulfaphenazole |
526-08-9 | >98% | 100mg |
$200.0 | 2022-02-28 | |
| DC Chemicals | DC26155-250 mg |
Sulfaphenazole |
526-08-9 | >98% | 250mg |
$400.0 | 2022-02-28 | |
| DC Chemicals | DC26155-1 g |
Sulfaphenazole |
526-08-9 | >98% | 1g |
$800.0 | 2022-02-28 | |
| BAI LING WEI Technology Co., Ltd. | 178125-1G |
Sulfaphenazole, 99% |
526-08-9 | 99% | 1G |
￥ 2645 | 2022-04-26 | |
| BAI LING WEI Technology Co., Ltd. | 178125-5G |
Sulfaphenazole, 99% |
526-08-9 | 99% | 5G |
￥ 9881 | 2022-04-26 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | S137259-100mg |
Sulfaphenazole |
526-08-9 | ≥98% | 100mg |
￥233.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | S137259-500mg |
Sulfaphenazole |
526-08-9 | ≥98% | 500mg |
￥932.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | S137259-1g |
Sulfaphenazole |
526-08-9 | ≥98% | 1g |
￥1624.90 | 2023-09-01 | |
| TRC | S689020-250mg |
Sulfaphenazole |
526-08-9 | 250mg |
$ 127.00 | 2023-09-06 | ||
| TRC | S689020-500mg |
Sulfaphenazole |
526-08-9 | 500mg |
$ 178.00 | 2023-09-06 |
Sulfaphenazole Suppliers
Audited Supplier
Audited Supplier
Sulfaphenazole Related Literature
-
Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
-
Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
-
Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
-
Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
-
Jason Wan Lab Chip, 2020,20, 4528-4538
Related Categories
- Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
- Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles
- Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
- Other Chemical Reagents
Additional information on Sulfaphenazole
Introduction to Sulfaphenazole (CAS No. 526-08-9)
Sulfaphenazole, a compound with the chemical name 4-(2-hydroxyethylamino)benzenesulfonamide, is a well-known sulfonamide antibiotic that has been widely studied and utilized in the field of pharmaceutical chemistry. Its CAS number, 526-08-9, uniquely identifies it in chemical databases and literature, facilitating accurate referencing and research. This introduction delves into the properties, applications, and recent advancements in the study of Sulfaphenazole, highlighting its significance in modern medicine.
The chemical structure of Sulfaphenazole consists of a benzene ring substituted with a sulfonamide group and an amino ethyl chain. This configuration contributes to its antimicrobial properties, making it effective against a range of bacterial infections. The sulfonamide moiety is particularly crucial, as it interacts with bacterial enzymes involved in folic acid synthesis, thereby inhibiting bacterial growth. This mechanism of action has been a cornerstone in the development of antibiotics since the mid-20th century.
In recent years, researchers have been exploring novel applications and derivatives of Sulfaphenazole to enhance its therapeutic efficacy and reduce potential side effects. One significant area of research has focused on modifying the compound to improve its bioavailability and target specificity. For instance, studies have investigated the use of prodrugs that release Sulfaphenazole in a controlled manner within the body, potentially reducing gastrointestinal irritation and increasing overall effectiveness.
Another exciting development in the field has been the investigation of Sulfaphenazole's potential role in combination therapies. By pairing Sulfaphenazole with other antibiotics or antiviral agents, researchers aim to create synergistic effects that can overcome drug resistance. This approach has shown promise in treating multidrug-resistant infections, where traditional antibiotics alone may be insufficient.
The pharmacokinetic profile of Sulfaphenazole has also been a subject of extensive research. Studies have examined how different factors, such as dosage form and patient demographics, influence the compound's absorption, distribution, metabolism, and excretion (ADME). These insights have led to optimized dosing regimens that maximize therapeutic benefits while minimizing adverse effects. For example, recent findings suggest that extended-release formulations of Sulfaphenazole may provide more consistent blood levels compared to immediate-release versions.
Furthermore, the toxicological aspects of Sulfaphenazole have been thoroughly evaluated to ensure its safety for clinical use. Animal studies have provided valuable data on potential hepatotoxicity and renal impairment associated with high doses or prolonged use. Based on these findings, regulatory agencies have established guidelines for safe administration, including maximum daily doses and monitoring requirements for patients receiving long-term therapy.
Advances in computational chemistry have also played a significant role in understanding the interactions between Sulfaphenazole and biological targets. Molecular modeling techniques allow researchers to predict how Sulfaphenazole binds to bacterial enzymes at an atomic level. This information can guide the design of new derivatives with improved properties or reduced toxicity. Additionally, machine learning algorithms are being employed to identify potential drug-drug interactions involving Sulfaphenazole, further enhancing patient safety.
The global impact of Sulfaphenazole cannot be overstated. It remains a vital component in treating various infections worldwide and has been particularly valuable in resource-limited settings where access to newer antibiotics may be limited. Ongoing research aims to expand its applications beyond traditional bacterial infections, such as exploring its potential use in antifungal therapies or as a chemopreventive agent against certain types of cancer.
In conclusion, Sulfaphenazole (CAS No. 526-08-9) is a cornerstone compound in antibiotic therapy with a rich history of medical applications. Recent advancements in pharmaceutical research continue to uncover new possibilities for its use and improvement. By leveraging modern techniques such as prodrug development, combination therapies, pharmacokinetic optimization, and computational modeling, scientists are working towards enhancing its therapeutic potential while ensuring patient safety. The continued study of Sulfaphenazole underscores its enduring importance in addressing global health challenges.
526-08-9 (Sulfaphenazole) Related Products
- 1420043-53-3(Sulfaphenazole-(sulfanilamide ring-13C6))
- 2590-02-5(Benzenesulfonamide, N-(1-phenyl-1H-pyrazol-5-yl)-)
- 59440-82-3(Benzenesulfonamide,4-[[(phenylamino)thioxomethyl]amino]-N-(1-phenyl-1H-pyrazol-5-yl)-)
- 59646-83-2(Benzenesulfonamide,4-[[(phenylamino)carbonyl]amino]-N-(1-phenyl-1H-pyrazol-5-yl)-)
- 855-91-4(N4-Acetylsulfaphenazole)
- 1420043-51-1(Sulfapyrazole-(sulfanilamide ring-13C6))
- 374632-53-8(Benzenesulfonamide, N-(1-phenyl-1H-pyrazol-5-yl)-4-(2-propenyl)-)
- 852-19-7(4-amino-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)benzene-1-sulfonamide)
- 18179-65-2(Benzenesulfonamide,4-amino-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-, sodium salt (1:1))
- 183583-70-2(Benzenesulfonamide,4-amino-N-[1-(3,4-dichlorophenyl)-1H-pyrazol-5-yl]-)
